BioLife Solutions Stock Price, News & Analysis (NASDAQ:BLFS)

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 12 month price objectives for BioLife Solutions' shares. Their BLFS share price targets range from $22.00 to $28.00. On average, they anticipate the company's stock price to reach $24.60 in the next twelve months. This suggests a possible upside of 85.7% from the stock's current price.
View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts.

BioLife Solutions' stock was trading at $18.20 at the beginning of the year. Since then, BLFS shares have decreased by 27.2% and is now trading at $13.25.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our BLFS earnings forecast.

BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings data on Thursday, November, 9th. The medical equipment provider reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.09. The medical equipment provider had revenue of $33.33 million for the quarter, compared to the consensus estimate of $33.28 million. BioLife Solutions had a negative net margin of 66.04% and a negative trailing twelve-month return on equity of 12.70%.

BioLife Solutions issued an update on its third quarter 2023 earnings guidance on Thursday, October, 19th. The company provided EPS guidance of for the period. The company issued revenue guidance of $33.30 million-$33.30 million, compared to the consensus revenue estimate of $32.72 million.

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional investors include Fred Alger Management LLC (4.11%), Invesco Ltd. (2.42%), William Blair Investment Management LLC (1.55%), Ameriprise Financial Inc. (1.22%), New York State Common Retirement Fund (0.96%) and Jennison Associates LLC (0.93%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Geraint Phillips, Greef Roderick De, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Sarah Aebersold, Todd Berard, Troy Wichterman and Walter Villiger.
View institutional ownership trends.

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.